ArticleJournal of thoracic disease2026
Hemoglobin glycation index and mortality risk in severe community-acquired pneumonia: a retrospective study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hemoglobin glycation index (HGI), which reflects discrepancies between glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG), has been linked to poor outcomes across various diseases. This study aims to clarify its prognostic value in patients with community-acquired pneumonia (CAP), a critical concern for clinicians, by evaluating the association between HGI and all-cause mortality in CAP requiring intensive care unit (ICU) monitoring, specifically examining potential non-linear relationships and subgroup-specific effects. Methods: The Medical Information Mart for Intensive Care IV (MIMIC-IV) database was used for this retrospective cohort analysis. HGI was calculated by linear regression of HbA1c on FPG. Kaplan-Meier and Cox regression analyses were used to evaluate the association between HGI and all-cause mortality. Restricted cubic spline (RCS) and threshold effect analyses examined non-linear relationships, and subgroup analyses explored effect heterogeneity. Results: The research enrolled a cohort of 1,674 individuals diagnosed with CAP for investigation. The all-cause mortality rates of patients within 30 days and 90 days were 25.08% and 33.92% respectively. We divided the patients into four groups (Q1-Q4) based on quartiles. Cox regression showed that Q3 had the lowest mortality risk at 30 days [hazard ratio (HR) =0.46; 95% confidence interval (CI): 0.29-0.74; P<0.001] and 90 days (HR =0.44; 95% CI: 0.29-0.69; P<0.001), compared to Q1 (the lower HGI). RCS revealed an L-shaped association, with inflection points near -0.32. Subgroup analysis showed a stronger association in elderly patients (P=0.01). Conclusions: HGI is independently associated with mortality in patients with CAP, with a non-linear L-shaped relationship. Lower HGI levels are associated with a higher risk, and HGI may serve as a valuable marker for early risk stratification, particularly in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.